anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: This study aims to investigate how subjective aging influences the psychological and behavioral responses of older individuals, specifically focusing on the associations between subjective aging and longitudinal changes in biological age.
METHODS: This is a retrospective cohort study retrieving data from the Taiwan Longitudinal Study on Aging (TLSA), over a 4-year follow-up period. Subjective aging is assessed by asking participants if they perceive themselves as old, while frailty is measured using a frailty index comprising 34 deficits from various domains. Participants are categorized into three groups based on their chronological age. The association between subjective aging and transition of biological age (as indicated by an increased frailty index) from 2011 to 2015 is examined using logistic regression models.
RESULTS: The study consisted of 2412 participants, who were categorized into middle-age (n = 1,082), young-old (n = 779), and old-old (n = 551) groups. Among them, individuals exhibiting subjective aging at baseline were more likely to be older in chronological age, female, illiterate, and unemployed, compared to those without subjective aging. The adjusted odds ratios (aORs) for the association between subjective aging and an increased biological age were 1.72 [95% CI: 0.88-3.34], 1.61 [0.77-3.37], and 1.08 [0.65-1.80], in the middle-age, young-old, and old-old groups, respectively.
DISCUSSIONS: No significant associations were found between changes in biological age and subjective aging across various chronological age groups. Notably, within the younger age group, a discernible trend towards an association was observed, indicating the potential age-related nuances in the complex interrelation between subjective age, biological aging, and chronological aging.
Dysarthria, a motor speech disorder that impacts articulation and speech clarity, presents significant challenges for Automatic Speech Recognition (ASR) systems. This study proposes a groundbreaking approach to enhance the accuracy of Dysarthric Speech Recognition (DSR). A primary innovation lies in the integration of the SepFormer-Speech Enhancement Generative Adversarial Network (S-SEGAN), an advanced generative adversarial network tailored for Dysarthric Speech Enhancement (DSE), as a front-end processing stage for DSR systems. The S-SEGAN integrates SEGAN's adversarial learning with SepFormer speech separation capabilities, demonstrating significant improvements in performance. Furthermore, a multistage transfer learning approach is employed to assess the DSR models for both word-level and sentence-level DSR. These DSR models are first trained on a large speech dataset (LibriSpeech) and then fine-tuned on dysarthric speech data (both isolated and augmented). Evaluations demonstrate significant DSR accuracy improvements in DSE integration. The Dysarthric Speech (DS)-baseline models (without DSE), Transformer and Conformer achieved Word Recognition Accuracy (WRA) percentages of 68.60% and 69.87%, respectively. The introduction of Hierarchical Attention Network (HAN) with the Transformer and Conformer architectures resulted in improved performance, with T-HAN achieving a WRA of 71.07% and C-HAN reaching 73%. The Transformer model with DSE + DSR for isolated words achieves a WRA of 73.40%, while that of the Conformer model reaches 74.33%. Notably, the T-HAN and C-HAN models with DSE + DSR demonstrate even more substantial enhancements, with WRAs of 75.73% and 76.87%, respectively. Augmenting words further boosts model performance, with the Transformer and Conformer models achieving WRAs of 76.47% and 79.20%, respectively. Remarkably, the T-HAN and C-HAN models with DSE + DSR and augmented words exhibit WRAs of 82.13% and 84.07%, respectively, with C-HAN displaying the highest performance among all proposed models.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.

In a 4-week, placebo-controlled trial of VYVANSE in pediatric patients ages 6 to 12 years old with ADHD, there was a dose-related decrease in weight in the VYVANSE groups compared to weight gain in the placebo group. Additionally, in studies of another stimulant, there was slowing of the increase in height [see Adverse Reactions (6.1)].

Closely monitor growth (weight and height) in VYVANSE-treated pediatric patients. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. VYVANSE is not approved for use in pediatric patients below 6 years of age [see Use in Specific Populations (8.4)].
In the SM condition all consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
The invention discloses an antibody of anti-human CD47 protein, a nucleic acid molecule and application thereof, and relates to the technical field of preparation of CD47 antibodies. The provided antibody against human CD47 protein has higher affinity with natural antigen (CD 47) protein, is a murine monoclonal antibody, and can specifically recognize CD47 protein expressed in cells such as human cell line MD-MB-231 (breast cancer cells) and Jurkat. Therefore, the kit can be used for developing detection or diagnosis reagents and kits taking human CD47 protein as a diagnosis marker. The anti-CD 47 antibody does not cause human erythrocyte agglutination at a certain concentration. Can be used for further humanization engineering so as to target drug administration. In addition, the anti-CD 47 antibody provided by the invention can effectively inhibit proliferation of tumor cells such as leukemia cells, breast cancer cells and the like, and has good tumor inhibition activity.
Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
BACKGROUND: Patients, caregivers, and healthcare professionals often describe a "good death" as a pain-free process. However, many patients experience pain during their last weeks of life. Advance directives (ADs) are legally binding documents that allow individuals to express their wishes for end-of-life care which should include management of their pain.
METHODS: An interprofessional team conducted a comprehensive analysis of ADs from all 50 states and the District of Columbia to assess the inclusion of language that reflects patients' wishes for pain relief at the end of life.
RESULTS: Thirty-seven (73%) of the 51 entities examined reflected the prototypical directive, containing explicit instructions for withholding or withdrawing interventions that may prolong suffering rather than options for treating pain. Of these, 12 (24%) did not include the word "pain". Only 14 states (27%) provided clear guidance for managing pain. Unexpectantly, researchers found that 13 (25%) addressed the common fears of patients, caregivers, and healthcare teams when using opioids to relieve suffering, such as addiction, sedation, appetite, or respiratory suppression, and hastening death.
CONCLUSION: The majority of ADs reviewed lacked clear and comprehensive measures for addressing pain relief. This deficiency may contribute to the undertreatment of pain and amplify the anxiety felt by patients, families, and healthcare providers when making end-of-life decisions. The results highlight the need for improvements in ADs to help ensure that patients' wishes regarding pain management are adequately addressed, documented and respected.
Dexamethasone tablets, USP are available for oral administration containing 2 mg of dexamethasone, USP. Each tablet contains the following inactive ingredients: corn starch, lactose monohydrate, and magnesium stearate.

Dexamethasone, a synthetic adrenocortical steroid, is a white to almost-white, crystalline powder. It is practically insoluble in water, very slightly soluble in ether, slightly soluble in methylene chloride and chloroform, and sparingly soluble in methanol, ethanol (96 %), acetone and 1,4 dioxane. The molecular formula is C 22H 29FO 5. The molecular weight is 392.5 g/mol. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene,3,20-dione and the structural formula is:
<P>PROBLEM TO BE SOLVED: To provide an adhesive preparation for percutaneously administering a medicine liquid at room temperature or at temperatures near to the room temperature, which uses a polyisobutylene-based adhesive as an adhesive, inhibits the bleeding of the medicine, and has sufficient adhesive characteristics.  <P>SOLUTION: This adhesive preparation 10 is characterized by laminating an adhesive layer 2 to one side of a support 1. This adhesive layer 2 comprises a 12 to 28C branched monohydric alcohol, the medicine (excluding the free base of bisoprolol) liquid at room temperature or near to the room temperature, and a polyisobutylene-based adhesive. Thereby, the compatibility of the polyisobutylene-based adhesive with the medicine can specifically be enhanced. Consequently, the amount of the medicine can be increased, and the bleeding of the free base of the bisoprolol from the adhesive layer can be prevented. Sufficiently adhesive characteristics on practical aspects can be obtained.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: Debridement, antibiotics, and implant retention (DAIR) are the mainstays surgical treatment for acute periprosthetic joint infection (PJI). However, reoperation following DAIR is common and the risk factors for DAIR failure remain unclear. This study aimed to assess the perioperative characteristics of patients who failed initial DAIR treatment.
METHODS: A retrospective review was conducted on 83 patients who underwent DAIR for acute PJI within 3 months following index surgery from 2011 to 2022, with a minimum one-year follow-up. Surgical outcomes were categorized using the Musculoskeletal Infection Society outcome reporting tool (Tiers 1 to 4). Patient demographics, laboratory data, and perioperative outcomes were compared between patients who had failed (Tiers 3 and 4) (n = 32) and successful (Tiers 1 and 2) (n = 51) DAIR treatment. Logistic regression was also performed.
RESULTS: After logistic regression, Charlson Comorbidity Index (odds ratio [OR]: 1.57; P = .003), preoperative C-reactive protein (OR: 1.06; P = .014), synovial white blood cell (OR: 1.14; P = .008), and polymorphonuclear cell (PMN%) counts (OR: 1.05; P = .015) were independently associated with failed DAIR. Compared with total hip arthroplasty, total knee arthroplasty patients (OR: 6.08; P = .001) were at increased risk of DAIR failure. The type of organism and time from primary surgery were not correlated with DAIR failure.
CONCLUSIONS: Patients who had failed initial DAIR tended to have significantly higher Charlson Comorbidity Index, C-reactive protein, synovial white blood cell, and PMN%. The total knee arthroplasty DAIRs were more likely to fail than the total hip arthroplasty DAIRs. These characteristics should be considered when planning acute PJI management, as certain patients may be at higher risk for DAIR failure and may benefit from other surgical treatments.
LEVEL OF EVIDENCE: III.
After consent and screening, patients will be initiated on 5mg or 10mg per day of olanzapine. Olanzapine doses will be titrated to 10-20 mg of olanzapine over one week, to a maximum of 20mg by day 21. Patients will also receive either topiramate (25mg bid titrated over 18 days to 150 mg bid. with flexibility to titrate to 200mg bid) or matched placebo. Topiramate will be initiated at a dose of 25 mg bid and will be increased by 25 mg bid every three days as tolerated. Patients will be evaluated by a blinded (to treatment status and adverse events) rater.
This study seeks to develop a theory-based clinical decision-making framework for the training of walking recovery after stroke based on how different biomechanical patterns of walking illustrate distinct motor control deficits. Each participant will complete 12 sessions (three times a week for four weeks) of either INCLINE, DECLINE, or CONTROL training. Clinical and biomechanical outcome measures will be collected pre- and post-training and after a one-month follow-up period. In addition, the investigators will collect a battery of clinical outcome measures before and after training. Spatiotemporal variables (including SSWS) will be collected before and after each session. All clinical and biomechanical assessments will be conducted by an evaluator blinded to training group allocation.
In sheep infected with bovine leukemia virus (BLV), transcription of structural, enzymatic, and accessory genes is silenced. However, the BLV provirus transcribes a series of non-coding RNAs that remain undetected by the host immune response. Specifically, three RNAs (AS1-L, AS1-S, and AS2) are consistently expressed from the antisense strand, originating from transcriptional initiation at the 3'-Long Terminal Repeat (LTR). To investigate the role of these non-coding RNAs in viral replication and pathogenesis, a reverse genetics approach was devised, capitalizing on a mechanistic disparity in transcription initiation between the 5' and 3' promoters. A two-nucleotide mutation (GG>TA) in the TFIIB-recognition element (BRE) impaired antisense transcription originating from the 3'-LTR. In the context of the provirus, this 2bp mutation significantly diminished the expression of antisense RNAs, while not notably affecting sense transcription. When inoculated to sheep, the mutated provirus was infectious but exhibited reduced replication levels, shedding light on the role of antisense transcription in vivo. In comparison to lymphoid organs in sheep infected with a wild-type (WT) provirus, the mutant demonstrated alterations in both the spatial distribution and rates of cell proliferation in the lymph nodes and the spleen. Analysis through RNA sequencing and RT-qPCR unveiled an upregulation of the Hmcn1/hemicentin-1 gene in B-lymphocytes from sheep infected with the mutated provirus. Further examination via confocal microscopy and immunohistochemistry revealed an increase in the amount of hemicentin-1 protein encoded by Hmcn1 in peripheral blood mononuclear cells (PBMCs) and lymphoid organs of sheep infected with the mutant. RNA interference targeting Hmcn1 expression impacted the migration of ovine kidney (OVK) cells in vitro. In contrast to the WT, the mutated provirus showed reduced oncogenicity when inoculated into sheep. Collectively, this study underscores the essential role of antisense transcription in BLV replication and pathogenicity. These findings may offer valuable insights into understanding the relevance of antisense transcription in the context of human T-cell leukemia virus (HTLV-1).
See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
The present invention relates generally to a technology platform, referred to as PhytologixTM for the discovery of novel bioactive pharmaceutical, nutraceutical and cosmetic agents. Specifically, this invention includes an integrated system for the collection of medicinal plants and creation of informatic databases related to these plants. This invention also relates to an improved standardized extraction and fractionation process, which provides significant advantages over the prior art in the terms of simplicity, efficiency of the separations, the quality of the library, low cost of the process and extraordinary throughput. This invention provides details to the structure dereplication process by utilizing the technology such as HPLC/PDA/MS coupled with high throughput bioassay data and an internal pure compound library. It has been proven to be much more efficient and accurate when compared to the prior art methods. Finally, the PhytologixTM platform has been approved as a realistic and efficient process by the determination of the whole process of discovery and development of natural COX-2 and tyrosinase inhibitors as novel nutraceutical and cosmetic products.
The application discloses an application of neferine in preparing a medicine for inhibiting SARS-CoV-2 infection, belonging to the technical field of natural medicines. The experimental result shows that Neferine can safely and effectively inhibit the infection of SARS-CoV-2 pseudovirion on host cells. With the increase of the concentration of neferine, the infection rate of the pseudovirion to the cells is gradually reduced. Effect of neferine on half Inhibitory Concentration (IC) of SARS-CoV-2 pseudovirus  50  ) It was 0.36. Mu.M. In addition, the CCK8 results show half the toxic concentration (CC) of neferine  50  ) Selectivity index of neferine was calculated at 29.17 μ M (SI = CC)  50  /IC  50  ) It was 81.03. The stage of infection of neferine on SARS-CoV-2 was confirmed by administration at different time points and by VSV-G pseudovirus exclusion experiments. The invention proves that the neferine has the function of inhibiting SARS-CoV-2 infection and can be used for preparing the medicine for inhibiting SARS-CoV-2 infection.
Cerebral small vessel disease (cSVD) accounts for 20-25% of all strokes and is the most common cause of vascular cognitive impairment (VCI) as well as a major contributor to mixed dementia, potentially interacting with Alzheimer's disease. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion. This is a prospective, open-label randomized controlled clinical trial with blinded endpoint assessment (PROBE). Participants that complete a 14-day run-in period will be randomized to 30 days of either: a) RIC performed once per day on one arm, or b) RIC performed twice per day on one arm. Each RIC session will consist of 4 cycles of unilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes, administered by modified blood pressure monitor (under an Investigational Trail Authorization from Health Canada). The primary outcome is tolerability, defined as the proportion in each trial arm that complete 80% or more of the assigned RIC sessions. Secondary outcomes will include pain scores, cognition, and MRI markers of cerebral blood flow and white matter integrity.
Increasing microRNAs (miRNAs) have been confirmed to be inextricably linked to various diseases, and the discovery of their associations has become a routine way of treating diseases. To overcome the time-consuming and laborious shortcoming of traditional experiments in verifying the associations of miRNAs and diseases (MDAs), a variety of computational methods have emerged. However, these methods still have many shortcomings in terms of predictive performance and accuracy. In this study, a model based on multiple graph convolutional networks and random forest (MGCNRF) was proposed for the prediction MDAs. Specifically, MGCNRF first mapped miRNA functional similarity and sequence similarity, disease semantic similarity and target similarity, and the known MDAs into four different two-layer heterogeneous networks. Second, MGCNRF applied four heterogeneous networks into four different layered attention graph convolutional networks (GCNs), respectively, to extract MDA embeddings. Finally, MGCNRF integrated the embeddings of every MDA into the features of the miRNA-disease pair and predicted potential MDAs through the random forest (RF). Fivefold cross-validation was applied to verify the prediction performance of MGCNRF, which outperforms the other seven state-of-the-art methods by area under curve. Furthermore, the accuracy and the case studies of different diseases further demonstrate the scientific rationale of MGCNRF. In conclusion, MGCNRF can serve as a scientific tool for predicting potential MDAs.
Norepinephrine is a potent vasopressor used to treat hypotension in the critical care setting. Recent studies have looked at norepinephrine's use in the obstetric setting, and have shown that it can be used safely and also has favourable hemodynamic properties when compared to phenylephrine, with less bradycardia and less depression of cardiac output. These studies have been limited to using norepinephrine as an infusion and there is limited data with it being used as a bolus to prevent hypotension. A recent study was undertaken at Mount Sinai hospital to determine the ED90 of norepinephrine to treat post spinal hypotension. Secondary outcome data from this trial showed that the incidence of bradycardia associated with this treatment is approximately 7.5%, several times less when compared to the reported 30% with phenylephrine. It would therefore be prudent at this stage to undertake a randomized trial comparing the hemodynamic profile of phenylephrine (our standard practice) and norepinephrine used as intermittent boluses to prevent hypotension and avoid decrease in heart rate during cesarean delivery.
Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
PURPOSE: While the relationship between eosinophilia and tumors has been extensively studied, eosinophilia is primarily observed clinically after tumor development, with no prior reports of eosinophilia occurring before tumor onset. This case report presents a unique instance of eosinophilia preceding the development of gastric cancer in an old male patient.
METHODS: The patient was evaluated after being diagnosed with gastric cancer. Investigations included physical examinations, hematological evaluations, molecular assays for genetic variations associated with eosinophilia, tumor marker assessments, staging using the AJCC system, histopathological examinations, and comprehensive sequencing of tumor tissue.
RESULTS: The patient exhibited disseminated erythematous macules and had a history of eosinophilia. Genetic testing for germline variations associated with eosinophilia was negative, and molecular assays did not detect significant genetic alterations linked to clonal eosinophilia. Staging revealed T1N0MX gastric cancer, with histopathology showing high-grade intraepithelial neoplasia and positive PD-L1 expression. Notably, sequencing identified mutations in the NOTCH1 and NOTCH2 genes, which are known to regulate eosinophil migration. After surgical intervention, pathological examinations confirmed high-grade squamous cell carcinoma in the esophagus and high-grade intraepithelial neoplasia in the stomach, without eosinophil infiltration. Surprisingly, the peripheral blood eosinophilia dramatically decreased following tumor resection.
CONCLUSION: This case underscores the potential for eosinophilia to occur prior to tumor development, challenging the current understanding of the relationship between eosinophilia and cancer. Further research is warranted to explore the implications of eosinophilia in cancer pathogenesis and its clinical significance.